GERM Performance — ETFMG Treatments Testing and Advancements ETF
Data updated: 2024-02-28
GERM returned −13.82% over one year to Dec 2023. The annualised 3-year return is −13.60%. The fund trailed its Health Care Equity category average: $100 invested three years ago grew to $64, against $97 for the category, and to $86 over one year, against $104. Volatility over the past three years was 30.23% a year. In the 12 months to Dec 2023 the fund took in a net $8.4M, and assets reached $12.78M.
GERM Growth of $100
What $100 invested in ETFMG Treatments Testing and Advancements ETF grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Health Care Equity category average over the same months.
| Period | GERM | Category average |
|---|---|---|
| 1 year (Jan 2023 – Dec 2023) | $86 | $104 |
| 3 years (Jan 2021 – Dec 2023) | $64 | $97 |
| Since data start (Apr 2020 – Dec 2023) | $81 | $139 |
GERM Trailing Returns
Total returns to Dec 2023, from SEC N-PORT.
| Period | Total return |
|---|---|
| 1 year | −13.82% |
| 3 years (annualised) | −13.60% |
GERM Annual Returns
Calendar-year total returns of ETFMG Treatments Testing and Advancements ETF, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2023 | −13.82% |
| 2022 | −34.91% |
| 2021 | +14.97% |
| 2020 (Apr–Dec) | +25.59% |
GERM Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 | +4.9% | −10.0% | −3.1% | −0.7% | −1.3% | +0.9% | 0.0% | −5.4% | −8.3% | −9.3% | +8.4% | +11.7% |
| 2022 | −21.4% | −2.0% | −0.5% | −15.1% | +1.2% | −0.5% | +7.2% | −6.4% | −11.2% | +9.0% | +5.9% | −3.4% |
| 2021 | +26.4% | −2.8% | −7.3% | +7.5% | −0.4% | +5.7% | +2.6% | +7.0% | −6.7% | −7.5% | +4.6% | −9.8% |
| 2020 | — | — | — | 0.0% | 0.0% | +13.7% | +11.3% | −13.8% | +1.5% | −1.5% | +22.8% | −6.3% |
GERM Risk
Risk measures from monthly returns over Jan 2021 – Dec 2023.
- 3-year volatility (annualised): 30.23%
- 3-year Sharpe ratio: -0.60 (vs 4.5% risk-free rate)
- Best month: +26.35% (Jan 2021)
- Worst month: −21.41% (Jan 2022)
GERM Fund Flows
Monthly money in and out of ETFMG Treatments Testing and Advancements ETF, from SEC Form N-PORT.
- 12-month net flow: $8.4M
- 12-month gross sales (incl. reinvestments): $0
- Sales ÷ redemptions: -0.00×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Dec 2023 | $0 | −$901K | $901K |
| Nov 2023 | $0 | −$877K | $877K |
| Oct 2023 | $0 | $0 | $0 |
| Sep 2023 | $0 | $0 | $0 |
| Aug 2023 | $0 | −$1.0M | $1.0M |
| Jul 2023 | $0 | −$1.0M | $1.0M |
| Jun 2023 | $0 | $0 | $0 |
| May 2023 | $0 | −$1.0M | $1.0M |
| Apr 2023 | $0 | $0 | $0 |
| Mar 2023 | $0 | −$1.1M | $1.1M |
| Feb 2023 | $0 | $0 | $0 |
| Jan 2023 | $0 | −$2.4M | $2.4M |
GERM Assets Under Management
Net assets of ETFMG Treatments Testing and Advancements ETF by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2023-12-31 | $12.78M |
| 2023-09-30 | $13.45M |
| 2023-06-30 | $17.61M |
| 2023-03-31 | $18.92M |
| 2022-12-31 | $24.25M |
| 2022-09-30 | $21.76M |
| 2022-06-30 | $25.65M |
| 2022-03-31 | $34.17M |
| 2021-12-31 | $49.98M |
| 2021-09-30 | $63.48M |
| 2021-06-30 | $56.04M |
| 2021-03-31 | $56.67M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.